Announced Tue, 7 Jul · 15:27 IST
Routine Reg 74(5) demat compliance certificate submitted for Jun 2026 quarter
Compliance View source PDF
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.7%1-day move
₹703.00
prior close
₹699.50
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-2.7+0.1+0.9+2.0+0.8+1.4————
Up moveDown movePending
AI summary
Aarti Pharmalabs filed a routine compliance certificate under SEBI Regulation 74(5) for the quarter ended June 30, 2026. The certificate from their Registrar MUFG Intime India confirms that share dematerialisation requests received during the quarter were processed, accepted or rejected by depositories, and physical share certificates were cancelled after verification. This is a standard quarterly regulatory filing with no material business or financial impact.
Likely market impact
Routine regulatory compliance filing. No material impact on shareholders or stock price.